These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 24302283)
1. Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs'. Yan Z Stat Med; 2013 Dec; 32(30):5484-6. PubMed ID: 24302283 [No Abstract] [Full Text] [Related]
2. Authors' reply to Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs". Jaki T; Pallmann P; Wolfsegger MJ Stat Med; 2013 Dec; 32(30):5487-8. PubMed ID: 24302284 [No Abstract] [Full Text] [Related]
3. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs. Jaki T; Pallmann P; Wolfsegger MJ Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551 [TBL] [Abstract][Full Text] [Related]
4. Sample size calculation for the Power Model for dose proportionality studies. Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313 [TBL] [Abstract][Full Text] [Related]
5. Carryover negligibility and relevance in bioequivalence studies. OcaƱa J; Sanchez O MP; Carrasco JL Pharm Stat; 2015; 14(5):400-8. PubMed ID: 26175204 [TBL] [Abstract][Full Text] [Related]
6. The subject-by-formulation interaction in multivariate bioequivalence. Cao L; Mathew T J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387 [TBL] [Abstract][Full Text] [Related]
8. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs. Chen YI; Huang CS Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611 [TBL] [Abstract][Full Text] [Related]
9. On sample size calculation in bioequivalence trials. Chow SC; Wang H J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):155-69. PubMed ID: 11381568 [TBL] [Abstract][Full Text] [Related]
10. Average bioequivalence for two-sequence two-period crossover design with incomplete data. Lee JY; Kim BC; Park SG J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389 [TBL] [Abstract][Full Text] [Related]
11. A note on sample size determination for bioequivalence studies with high-order crossover designs. Chen KW; Chow SC; Li G J Pharmacokinet Biopharm; 1997 Dec; 25(6):753-65. PubMed ID: 9697082 [TBL] [Abstract][Full Text] [Related]
12. The impact of baseline covariates on the efficiency of statistical analyses of crossover designs. Yan Z Stat Med; 2013 Mar; 32(6):956-63. PubMed ID: 22903413 [TBL] [Abstract][Full Text] [Related]
13. Bioequivalence trials with the incomplete 3 x 3 crossover design. Lim NK; Park SG; Stanek E Biom J; 2005 Oct; 47(5):635-43. PubMed ID: 16385904 [TBL] [Abstract][Full Text] [Related]
14. A comment on optimal allocations for bioequivalence studies. Senn S; Grieve AP Biometrics; 1999 Dec; 55(4):1314-5. PubMed ID: 11315090 [TBL] [Abstract][Full Text] [Related]
15. A method for the evaluation of individual bioequivalence. Endrenyi L Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334 [TBL] [Abstract][Full Text] [Related]
17. Two-stage designs for cross-over bioequivalence trials. Kieser M; Rauch G Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815 [TBL] [Abstract][Full Text] [Related]
18. The AB/BA crossover: past, present and future? Senn S Stat Methods Med Res; 1994 Dec; 3(4):303-24. PubMed ID: 7889225 [TBL] [Abstract][Full Text] [Related]
19. Modifications of sequential designs in bioequivalence trials. Zheng C; Zhao L; Wang J Pharm Stat; 2015; 14(3):180-8. PubMed ID: 25663282 [TBL] [Abstract][Full Text] [Related]
20. Sample size calculation for bioequivalence studies with high-order crossover designs. Qu RP; Zheng H Control Clin Trials; 2003 Aug; 24(4):436-9. PubMed ID: 12865037 [No Abstract] [Full Text] [Related] [Next] [New Search]